Ripple Software Achieves 96% Clinical Trial Retention
This is an article about portfolio company, Ripple Science.
ANN ARBOR, Mich., May 10, 2021 /PRNewswire-PRWeb/ — A white paper recently published by Ripple Science revealed that its flagship product, Ripple, empowered its customers to achieve >96% retention across all trials and 99% retention in 78.2% of completed trials, far outpacing industry averages.
Ripple Science is the leading provider of clinical trial software used by sites, CROs, and study sponsors to assist and automate the patient engagement workflow end-to-end, from first contact to study completion. Ripple has supported over 700 clinical trials involving over 240,000 patients globally, including a large number of Alzheimer’s, dementia, and CNS trials where patient engagement is particularly challenging.
View source version on iosconews.com: http://www.iosconews.com/news/state/article_487c5c48-9ff1-5bfc-b738-b8e526ce7730.html